Oil API

chello(John) -
online
5:12 chello(John): I hope the following helps your understanding, API = American Petroleum Institute.....The American Petroleum Institute reports inventory levels of US crude oil, gasoline and distillates stocks. The figure shows how much oil and product is available in storage.The indicator gives an overview of US petroleum demand. If the increase in crude inventories is more than expected, it implies weaker demand and is bearish for crude prices. The same can be said if a decline in inventories is less than expected. If the increase in crude is less than expected, it implies greater demand and is bullish for crude prices. The same can be said if a decline in inventories is more than expected.
gchu

Hold stock during earnings is a gambling. AAPL went down and came back a little, looks like investors still trying to digest the reports.
17:05:29
0

BK

High Demands  for iPhones
17:01:53
0

BK

AAPL going
17:01:06
0

BK

AAPL maybe will open 118.15..after Cramer pumps tonight
16:53:13
0

HarryBoxer

Apple guidance implies Q1 net income of ~$16.5-17.4 bln vs. $18.36 bln last year
16:50:38
0

HarryBoxer

Dec WTI crude oil fell about $0.43 to $49.36/barrel and is now -2.2% at $49.40/
16:49:37
0

Tawfic

Apple annual revenue fell for the first time since 2001, highlighting the slowdown in the smartphone market as well as intensifying competition, particularly from Chinese rivals. Not impressed!
16:49:33
4

HarryBoxer

DWTI explodes after hrs to 62 on API data
16:49:11
1

HarryBoxer

Post-earnings gainers: SCKT +24.6%, JNPR +8.8%, VRTX +6.7%, AKAM +6.6%, PNRA +6%, IRBT +3.7%, MRCY +2.9%
16:48:38
0

HarryBoxer

Array Biopharma and Pierre Fabre to present Phase 3 COLUMBUS trial at Society For Melanoma Research Congress on November 9

Findings from COLUMBUS evaluating the combination of encorafenib plus binimetinib ("combination") in patients with unresectable or metastatic BRAF-mutant melanoma will be presented as an oral, late-breaking abstract. Two data analyses from the NEMO Phase 3 trial will also be presented, which evaluated binimetinib in patients with NRAS-mutant melanoma.
Read More
16:47:46
0

HarryBoxer

JNPR pops 2.25 JNPR Juniper Networks beats by $0.06, beats on revs
16:46:23
0

HarryBoxer

EW DIVES $14!~!!

EW Edwards Lifesciences reports EPS in-line, misses on revs; guides Q4 EPS in-line, revs below consensus          
16:45:47
0

HarryBoxer

NCR NCR Corp beats by $0.06, beats on revs; guides Q4 EPS in-line, revs above consensus; guides FY16 EPS above consensus, revs above consensus
16:45:03
0

HarryBoxer

CMG -$9 at 396
16:44:12
0

HarryBoxer

CMG Chipotle Mexican Grill prelim Q3 GAAP EPS $0.27 vs $1.62 Capital IQ Consensus Estimate; revs $1.04 bln vs $1.09 bln Capital IQ Consensus Estimate; comps -24.9%
16:43:14
0

HarryBoxer

Vertex today reiterated its 2016 revenue guidance for ORKAMBI and KALYDECO (Issued on September 28). The company also reiterated guidance for its 2016 combined non-GAAP R&D and SG&A expenses. The guidance is summarized below:

    ORKAMBI: The company continues to expect total 2016 product revenues for ORKAMBI of $950 to $990 million.
    KALYDECO: The company continues to expect total 2016 product revenues for KALYDECO of $685 to $705 million.
    Vertex continues to expect that its combined non-GAAP R&D and SG&A expenses in 2016 will be in the range of $1.18 to $1.23 billion.

Read More
16:42:28
0

Swing Trading
HarryBoxer

RSYS RadiSys beats by $0.03, beats on revs; guides Q4 EPS in-line, revs below consensus
16:42:03
0

HarryBoxer

AKAM pops $4     AKAM Akamai Tech beats by $0.07, beats on
16:41:24
0

HarryBoxer

PNRA pops 13
  PNRA Panera Bread beats by $0.03, reports revs in-line; guides Q4 EPS in-line
16:40:47
0

HarryBoxer

VRTX Vertex Pharma jumps +5% up toward $83-level afterhours
16:40:14
0

1
0